Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

In der Einreichung gab Opthea Ltd an, dass es Jahresberichte unter dem SEC-Formular 20-F einreicht, welches von nicht in den USA ansässigen Unternehmen verwendet wird, um einen umfassenden Überblick ...

This is every investor's worst nightmare. In an update this week, we learned that Opthea has decided to cease development of its sozinibercept (OPT-302) treatment. OPT-302 had been a potential ...

Opthea last traded at 60 cents per share. Last week, we learned that Opthea has decided to cease development of its flagship sozinibercept (OPT-302) treatment. OPT-302 had been a potential ...

The studies of sozinibercept 2 mg (Opthea), also known as OPT-302, failed to meet their primary endpoint of improvement in best corrected visual acuity (BCVA) after a year of treatment when ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

For patients with treatment-naïve PCV, combining sozinibercept with ranibizumab may yield better 24-week functional and anatomical outcomes than monotherapy. Vascular endothelial growth factor ...

Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study. Opthea on Monday ...

Zusätzlich veröffentlichte Opthea positive Ergebnisse aus seiner Phase-2b-Studie zu Sozinibercept, die eine statistisch signifikante Verbesserung der Sehschärfe in Kombination mit der ...